New Japanese Global Clinical Trial Requirements Could Help MNCs – BIO-Asia Panel
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Efforts by Japanese regulators to better equip local pharmaceutical companies for the global marketplace could also pay dividends for Western multinationals looking to secure marketing authorization in Japan, according to a recent panel discussion during BIO-Asia in Tokyo